Pr Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Saclay University since 1999, a role he took following 10 years of practice of clinical immunology in Paris-Diderot University.
Pr Mariette has initiated a number of clinical research studies on long-term tolerance of biotherapies in autoimmune diseases: RATIO (Research Axed on Tolerance of Biotherapy) observatory) for anti-TNF, AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis). He initiated clinical trials in Sjögren’s syndrome with infliximab, hydroxychloroquine and belimumab. Recently, he worked on rheumatic adverse effects observed with immune checkpoint therapy of cancer and on immune modulators in the treatment of COVID-19 infection.
Pr Mariette is involved in basic research, leading a group working on pathogeny of Sjögren’s syndrome and rheumatoid arthritis, relationships between innate immunity and B-cell activation in autoimmunity, mechanism of action of methotrexate for decreasing immunogenicity of biologics, macrophages in rheumatoid arthritis and the relationships between autoimmunity and lymphoma.
Pr Mariette has been the President of the Scientific Committee of the EULAR meeting in Berlin in 2012 and has been from 2016 to 2020 the Chair of the EULAR standing committee on investigative rheumatology.
Pr Mariette is co-author of more than 500 publications referenced in PubMed with an H-index of 86 (Web of Science).
[International Symposium] 2022 Clinical Research Update of Sjögren's Syndrome
Current and future treatment of primary Sjögren’s syndrome